Effects of pulsatile L-DOPA treatment in the double lesion rat model of striatonigral degeneration (multiple system atrophy)

被引:22
|
作者
Stefanova, N
Lundblad, M
Tison, F
Poewe, W
Cenci, MA
Wenning, GK
机构
[1] Univ Innsbruck Hosp, Dept Neurol, A-6020 Innsbruck, Austria
[2] Lund Univ, Dept Physiol Sci, Div Neurobiol, Wallenberg Neurosci Ctr, Lund, Sweden
[3] Univ Bordeaux 2, Neurophysiol Lab, CNRS, UMR 5543, F-33076 Bordeaux, France
基金
奥地利科学基金会;
关键词
dyskinesia; motor improvement; MSA; rat model; levodopa; FosB;
D O I
10.1016/j.nbd.2003.11.025
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
We examined the role of a striatal lesion in the development of L-DOPA-induced abnormal involuntary movements (AlMs) using the double lesion rat model of striatonigral degeneration (SND), the underlying neuropathological substrate of parkinsonism associated with multiple system atrophy (MSA-P), in comparison to a Parkinson's disease (PD) rat model. L-DOPA administration reliably induced AlMs in SND and PD rats in a dose-dependent fashion. AlMs occurred significantly earlier in SND compared to PD rats. There was a mild, but significant, transient increase of orolingual AlMs during the first week of low-dose L-DOPA treatment in SND. Whereas L-DOPA significantly improved contralateral forelimb akinesia in PD rats, there was no beneficial effect in SND rats. Striatal FosB/DeltaFosB up-regulation in SND and PD rats correlated with the severity of L-DOPA-induced dyskinesias. Pulsatile L-DOPA administration in the double lesion SND rat model replicates salient features of the human disease MSA-P, including loss of the anti-akinetic L-DOPA response and induction of dyskinesias with transient orolingual predominance. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:630 / 639
页数:10
相关论文
共 50 条
  • [31] Effects of riluzole as "rescue therapy" in a MPTP+3-NP mouse model of striatonigral degeneration: Experimental rationale for its use in multiple system atrophy
    Diguet, E
    Fernagut, PO
    Scherfler, C
    Wenning, G
    Tison, F
    MOVEMENT DISORDERS, 2004, 19 : S387 - S387
  • [32] The effects of chronic L-DOPA therapy on pharmacodynamic parameters in a rat model of motor response fluctuations
    Lee, EA
    Lee, WY
    Kim, YS
    Kang, UJ
    EXPERIMENTAL NEUROLOGY, 2003, 184 (01) : 304 - 312
  • [33] Distinct Effects of Intranigral L-DOPA Infusion in the MPTP Rat Model of Parkinson's Disease
    Reksidler, Angela B.
    Lima, Marcelo M. S.
    Dombrowski, Patricia A.
    Barnabe, Gabriela F.
    Andersen, Monica L.
    Tufik, Sergio
    Vital, Maria A. B. F.
    JOURNAL OF NEURAL TRANSMISSION-SUPPLEMENT, 2009, (73): : 259 - 268
  • [34] Neuropathological and behavioral changes induced by various treatment paradigms with MPTP and 3-nitropropionic acid in mice: towards a model of striatonigral degeneration (multiple system atrophy)
    Stefanova, N
    Puschban, Z
    Fernagut, PO
    Brouillet, E
    Tison, F
    Reindl, M
    Jellinger, KA
    Poewe, W
    Wenning, GK
    ACTA NEUROPATHOLOGICA, 2003, 106 (02) : 157 - 166
  • [35] Neuropathological and behavioral changes induced by various treatment paradigms with MPTP and 3-nitropropionic acid in mice: towards a model of striatonigral degeneration (multiple system atrophy)
    Nadia Stefanova
    Zoe Puschban
    Pierre-Olivier Fernagut
    Emmanuel Brouillet
    François Tison
    Markus Reindl
    Kurt A. Jellinger
    Werner Poewe
    Gregor K. Wenning
    Acta Neuropathologica, 2003, 106 : 157 - 166
  • [36] The expression of the calcium binding protein calretinin in the rat striatum: Effects of dopamine depletion and L-DOPA treatment
    Mura, A
    Feldon, J
    Mintz, M
    EXPERIMENTAL NEUROLOGY, 2000, 164 (02) : 322 - 332
  • [37] Effects of a combination treatment of KD5040 and L-dopa in a mouse model of Parkinson's disease
    Ahn, Sora
    Song, Taek-Jin
    Park, Seong-Uk
    Jeon, Songhee
    Kim, Jongpil
    Oh, Joo-Young
    Jang, Jaehwan
    Hong, Sanhwa
    Song, Min-A
    Shin, Hye-Seoung
    Jung, Young-Rim
    Park, Hi-Joon
    BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2017, 17
  • [38] Effects of a combination treatment of KD5040 and L-dopa in a mouse model of Parkinson’s disease
    Sora Ahn
    Taek-Jin Song
    Seong-Uk Park
    Songhee Jeon
    Jongpil Kim
    Joo-Young Oh
    Jaehwan Jang
    Sanhwa Hong
    Min-A Song
    Hye-Seoung Shin
    Young-Rim Jung
    Hi-Joon Park
    BMC Complementary and Alternative Medicine, 17
  • [39] The combination of oral L-DOPA/rimonabant for effective dyskinesia treatment and cytological preservation in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia
    Gutierrez-Valdez, Ana L.
    Garcia-Ruiz, Ricardo
    Anaya-Martinez, Veronica
    Torres-Esquivel, Carmen
    Espinosa-Villanueva, Jesus
    Reynoso-Erazo, Leonardo
    Tron-Alvarez, Rocio
    Aley-Medina, Patricia
    Sanchez-Betancourt, Javier
    Montiel-Flores, Enrique
    Avila-Costa, Maria R.
    BEHAVIOURAL PHARMACOLOGY, 2013, 24 (08): : 640 - 652
  • [40] The effects of L-DOPA on gait abnormalities in a unilateral 6-OHDA rat model of Parkinson's disease
    Holden, Hannah
    Venkatesh, Shruti
    Budrow, Carla
    Nezaria, Sareen
    Coyle, Michael
    Centner, Ashley
    Lipari, Natalie
    McManus, Grace
    Bishop, Christopher
    PHYSIOLOGY & BEHAVIOR, 2024, 281